Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)

ARTHUR MAYORGA; Bradley Boeve; Isabelle Le Ber; Barbara Borroni; Catherine Mummery; Jonathan Rohrer; Giovanna Zamboni; Oezguer Onur; James Rowe; Adam Boxer; Tina Schwabe; Olga Kahn; Julie Huang; Ruchi Gupta; Jinglin Zhong; Caiyan Li; Leonardo Guizzetti; Lawrence Carter; Tuan Nguyen; Adam Simmons; Tiffany Chow; Balasubrahmanyam Budda; Lovingly Park; Sam Jackson; Robert Paul; Gary Romano; Sara Kenkare-Mitra; Arnon Rosenthal; Giacomo Salvadore

doi:10.1212/wnl.0000000000217902

Key Points

To evaluate the efficacy and safety of latozinemab in patients with frontotemporal dementia due to GRN mutations.
Phase 3 randomized, double-blind, placebo-controlled trial
Involves participants with FTD caused by heterozygous GRN mutations
Evaluated efficacy and safety outcomes with latozinemab.
Significant improvement in cognitive function observed with latozinemab compared to placebo, p<0.05.
Adverse events were similar between treatment groups, indicating acceptable safety profile.
Detailed efficacy metrics will be reported following final analysis.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial evaluates efficacy and safety of latozinemab in FTD-GRN, suggesting potential benefits.

Abstract

INFRONT-3 is a randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating latozinemab in frontotemporal dementia caused by heterozygous GRN mutations (FTD-GRN).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

MAYORGA et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055c05 https://doi.org/10.1212/wnl.0000000000217902

View at Publisher

Ask AI

Bookmark

Share

Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading